Conference call to discuss the Company’s pelabresib’s potential in first-line myelofibrosis with a comprehensive overview of the Phase 3 MANIFEST-2 trial results as presented at the recently-held ASH Annual Meeting will be held on December 11 at 10 am. Webcast Link
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MOR: